Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus.
In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...
Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...
Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide Study will investigate Pharmacokinetics and Safety KELOWNA, BC / ACCESS Newswire / April ...
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...
Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...
The combination met its primary endpoint of percent weight loss following an 8-week treatment period.
Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutideStudy will investigate Pharmacokinetics and Safety KELOWNA, BC / ACCESS Newswire / April 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback